Actin Cytoskeleton in Cancer Progression and Metastasis - Part A
- 1st Edition, Volume 355 - August 25, 2020
- Latest edition
- Editors: Lorenzo Galluzzi, Fernando Aranda Vega
- Language: English
Actin Cytoskeleton in Cancer Progression and Metastasis - Part A, Volume 355 in the International Review of Cell and Molecular Biology series, provides an overview of the roles of… Read more
Actin Cytoskeleton in Cancer Progression and Metastasis - Part A, Volume 355 in the International Review of Cell and Molecular Biology series, provides an overview of the roles of the actin cytoskeleton and some of its key structural regulators, including WASp, Paxillin, Myosin, Testin, L-Plastin and profilin, in central processes underlying cancer progression and metastasis, such as changes in cell morphology and gene expression, acquisition of migratory and invasive capabilities, and evasion from the immune response.
- Provides comprehensive and timely reviews on actin cytoskeleton and its regulators in cancer biology
- Offers a wide range of perspectives for basic and translational research
- Discusses opportunities and challenges for translating knowledge of tumor cell actin cytoskeleton into clinical applications
Advanced undergraduates, graduates, academics and researchers in the area of cancer biology
- Paxillin family of focal adhesion adaptor proteins and regulation of cancer cell invasion
- Nuclear actin in cancer biology
- Nuclear actin and myosin in chromatin regulation and maintenance of genome integrity
- The actin-bundling protein L-plastin—A double-edged sword: Beneficial for the immune response, maleficent in cancer
- Profilin choreographs actin and microtubules in cells and cancer
- Mechanics of actin filaments in cancer onset and progress
Kyle M. Alpha, Weiyi Xu and Christopher E. Turner
Stefan Zahler
Tomas Venit, S. Raza Mahmood, Martin Endara-Coll and Piergiorgio Percipalle
Elisabeth Schaffner-Reckinger and Raquel A. C. Machado
Morgan L. Pimm, Jessica Hotaling and Jessica L. Henty-Ridilla
Mohammad Tafazzoli-Shadpour, Ehsan Mohammadi and Elham Torkashvand
- Edition: 1
- Latest edition
- Volume: 355
- Published: August 25, 2020
- Language: English
LG
Lorenzo Galluzzi
Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.
Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals:
OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.
Affiliations and expertise
Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USAFA
Fernando Aranda Vega
Fernando Aranda holds a BSc in Biology (2006) and Biochemistry (2007) from the University of Navarra. Then, he specialized in different strategies of Cancer Immunotherapy with a MSc in Biomedical Research (2008), and a PhD Degree (2012) from the University of Navarra (Pamplona) – Cima University of Navarra. More than 12 years in translational research focus on antitumor immune responses and Cancer Immunotherapy. Author of 64 publications indexed in PubMed in prestigious international journals, with h-index 30 and 4,296 cites (October 2022). He completed the Program of Sara Borrell (ISCIII) -competitive Postdoctoral contract- in the Group of Immune Receptors of the Innate and Adaptive System (IDIBAPS), Barcelona (2016-2018). Co-author of 1 invention patent: Composition based on the fibronectin domain A for the treatment of melanoma - WO/2011/101332. In 2012, Fernando Aranda obtained a Scientific Award, "Profesor Durantez" II Edición, for the best scientific article in Tumor Immunology by Fundación LAIR. Recently, Fernando Aranda awarded a competitive Research Fellow contract “Miguel Servet tipo I” by Instituto de Salud Carlos III, to continue his independent researcher career (IP) in cancer immunotherapy issues. Specifically, he is involved in Translational Immunotherapy of Peritoneal Carcinomatosis. Currently, Fernando Aranda leads a research group in cooperation with Dr. Pedro Berraondo.
Affiliations and expertise
Fernando Aranda Vega, CIMA Universidad de Navarra, Program of Immunology and Immunotherapy, SpainRead Actin Cytoskeleton in Cancer Progression and Metastasis - Part A on ScienceDirect